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Transcriptional Inhibition of Hypertrophic Scars
by a Gene Silencer, Pyrrole–Imidazole Polyamide,
Targeting the TGF-b1 Promoter
Hisayo Washio1, Noboru Fukuda2, Hiroyuki Matsuda2, Hiroki Nagase3, Takayoshi Watanabe3,
Yoshiaki Matsumoto4 and Tadashi Terui1
Synthetic pyrrole–imidazole (PI) polyamides bind to the minor groove of double-helical DNA with high affinity
and specificity, and inhibit the transcription of corresponding genes. We examined the effects of a transforming
growth factor (TGF)-b1-targeted PI polyamide (Polyamide) on hypertrophic skin scars in rats. Hypertrophic scars
were created dorsally in rats by incisions. FITC-labeled Polyamide was injected to investigate its distribution
in the skin. Expression of TGF-b1, connective tissue growth factor (CTGF), collagen type1, and fibronectin
mRNAs was evaluated by reverse transcription PCR analysis. The extent of fibrosis and the expression of TGF-b1
were evaluated histologically and immunohistochemically. Polyamide was distributed in almost all nuclei of skin
cells. Expression of TGF-b1 mRNA reached a peak at 3 days after skin incision. Expression of CTGF and
extracellular matrix mRNAs was increased continuously even after the peak induction of TGF-b1 mRNA.
Injection of Polyamide completely inhibited both the development of scars and the induction of growth factors
and extracellular matrix mRNAs. The treatment also markedly inhibited fibrotic changes and reduced the
numbers of vimentin-positive spindle-shaped fibroblasts. Injection of Polyamide also reduced established
hypertrophic scars in rats. Thus, TGF-b1-targeted PI polyamide should be a feasible gene silencer for
hypertrophic scars and keloids.
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INTRODUCTION
Transforming growth factor-b (TGF-b) is a multifunctional
protein that regulates cell growth, differentiation, motility,
and extracellular matrix production in the normal wound-
healing process, but has also been implicated in excessive
scar formation and fibrotic disorders (Leask and Abraham,
2004; Lu et al., 2005; Phan et al., 2005; Kryger et al., 2007).
In addition, connective tissue growth factor (CTGF), a potent
growth factor, also stimulates the proliferation of mesench-
ymal cells and induces the production of extracellular matrix
downstream of TGF-b1 signaling in fibroblasts (Duncan et al.,
1999; Leask and Abraham, 2006). Elevated levels of CTGF
have been found in dermal fibrotic lesions such as
scleroderma (Abraham et al., 2000) and keloids (Igarashi
et al., 1996; Khoo et al., 2006), as well as in fibrotic lesions of
extracutaneous organs (Ito et al., 1998; Paradis et al., 1999).
To further support the role of CTGF in fibrosis, it has been
demonstrated that simultaneous co-injection of CTGF and
TGF-b1 caused a sustained fibrotic response in vivo, whereas
injection of TGF-b1 alone caused only a transient response
(Mori et al., 1999).
As medicines for hypertrophic scars, tranilast is known to
inhibit TGF-b (Shigeki et al., 1997) and corticosteroids
(Roques and Te´ot, 2008) have been used clinically. However,
tranilast is not specific for TGF-b and these medicines do not
completely improve hypertrophic scars and keloids. Nucleic
acid medicines have been developed to regulate molecules
responsible for various diseases that cannot be rescued with
present medicines. However, because of their DNA or RNA
structure, nucleic acid medicines have the disadvantage of
being easily degraded by nucleases in vivo. Pyrrole–imida-
zole (PI) polyamides, discovered from DNA-binding anti-
biotics, can bind sequence-specifically to double-strand DNA
and suppress the expression of target genes (Trauger et al.,
1996). As PI polyamides are low-molecular organic com-
pounds resistant to nucleolytic enzymes, they are capable
of being delivered to cells or tissues without using vectors
or delivery reagents (Dervan, 2001). Hence, PI polyamides
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show great promise as new medicines that might inhibit trans-
criptional control. Indeed, we have developed PI polyamides
as gene silencers for several diseases, including the design
and synthesis (Lai et al., 2005) of PI polyamides that target
TGF-b1 effectively, and we demonstrated specifically an
improvement to progressive renal disease (Matsuda et al.,
2006; Matsuda et al., 2011), restenosis of arteries after injury
(Yao et al., 2009) and cornea scarring after alkali burns (Chen
et al., 2010).
In the current study, to investigate transcriptional inhibi-
tion of hypertrophic scars by a PI polyamide targeted to
TGF-b1, we examined developing scars and established scars
in rats following treatments with PI polyamide.
RESULTS
Macroscopic and histopathological changes in the incised skin
By 14 days after the incisions, the skin was still depressed
with a pink colored line. On day 28, the incisional wound
became flatter and appeared as a white colored line. Then
the linear incisional wound elevated gradually. On day 42,
the incisional wound had elevated and appeared as white
colored lines of 0.7–1.0mm width, with a consistency that
was obviously harder to the touch compared with the
surrounding normal skin (Figure 1a).
Histological examination of the wound obtained at 14
days after the incision showed increases in collagen fibers,
blood vessels, and infiltrations of lymphocytes and neutro-
phils. On day 28, marked increases in fibroblasts and
collagen fibers were found with much fewer inflammatory
cells. On day 42, collagen fibers had changed to be more
hypertrophic and homogeneous (Figure 1a), which is very
similar to the pathological changes found in keloids and
hypertrophic scars. From these observations, we determined
that the formation of hypertrophic scars in the skin of a rat
model was completed 42 days after incision.
Changes in expression of growth factors and extracellular
matrices
Figure 1b shows changes in the mRNA expression of growth
factors (TGF-b1 and CTGF) and extracellular matrices
(collagen type1 and fibronectin) in incisional wounds. The
abundance of TGF-b1 mRNA was significantly (Po0.05)
increased at 2, 3, and 14 days after incision. A peak in
the increase in abundance of TGF-b1 mRNA was observed at
3 days after incision. The abundance of CTGF mRNA was
significantly (Po0.05) increased at 3 and 42 days after
incision showing two peaks. At 28 and 42 days after incision,
the abundance of collagen type1 mRNA was significantly
(Po0.05) increased and seems to have increased continu-
ously over this period. Likewise, the abundance of fibronectin
mRNA seems to have increased significantly (Po0.05) and
continuously from 3 to 42 days after incision.
Distribution of FITC-labeled TGF-b1-targeted PI polyamide in
rat skin
FITC-labeled TGF-b1-targeted PI polyamide (Polyamide) was
distributed in nuclei of almost all cells in incisional skin
wounds as shown in Figure 2. Even at 1 hour after a single-
dose subcutaneous injection, FITC-labeled Polyamide was
strongly localized in the nuclei of keratinocytes in the
epidermis and inflammatory cells, fibroblasts, and hair
follicle cells in the dermis. These distributions were mostly
present until 96 hours after the injection, although the
intensity was weaker than at 24 hours after injection.
Effects of Polyamide on the expression of TGF-b1
Figure 3a shows effects of increasing doses (1, 10, and
100mg) of Polyamide on expression of TGF-b1 mRNA in
incisional skin wounds. Injection of Polyamide (1, 10, and
100mg) significantly (Po0.01) inhibited the abundance of
TGF-b1 mRNA in a dose-dependent manner in skin tissues
obtained 3 days after incision. Subsequent experiments
therefore used 100 mg as the most effective dose of
Polyamide. Injection of 100mg of polyamide significantly
(Po0.01) inhibited the abundance of TGF-b1 protein, but
mismatch did not affect the abundance of TGF-b1 protein
(Figure 3b).
Effects of Polyamide on fibrosis in skin scars
Figure 4a shows effects of Polyamide on development,
histopathology, and stainings of TGF-b1 and vimentin in
hypertrophic scars in rat skin. Macroscopic findings showed
that injection of Polyamide completely inhibited the forma-
tion of hypertrophic scars after incision compared with
injection of saline (control). Histological findings also showed
that injection of Polyamide markedly inhibited fibrotic
degeneration of incisional wounds compared with control.
Immunohistochemically, injection of Polyamide consider-
ably reduced TGF-b1 staining and the number of vimentin-
positive spindle-shaped fibroblasts compared with control.
Effects of Polyamide on the expression of growth factors and
extracellular matrix mRNAs in scars
Figure 4b–e shows expression of growth factors (TGF-b1 and
CTGF) and extracellular matrices (collagen type1 and
fibronectin) in incisional wounds, 42 days after injection
of 0.1% acetic acid and 100mg of mismatch and Polyamide.
Single injections of Polyamide significantly (Po0.05) inhib-
ited abundance of TGF-b1, CTGF, collagen type1, and
fibronectin mRNAs in the skin, even on day 42. Injections
of acetic acid and mismatch did not appreciably affect
expression of the growth factors and the extracellular matrix
mRNAs in the skin wounds.
Effects of Polyamide on established scars
We examined the effects of injection of Polyamide on already
established scars in rats. Forty-two days after skin incisions,
polyamide was injected around the scars with a series of
either 3 or 10 injections at 3-day intervals. Grossly visible
scar elevations were inhibited with both the 3 and 10 groups
of injections in a frequency-dependent manner, but the
inhibition was obviously weak compared with the injection
of Polyamide on day 0. Immunohistochemical findings
showed that the intensity of TGF-b1 staining was clearly
suppressed in scars after both the 3 and 10 groups of
injections of Polyamide. The number of vimentin-positive
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spindle-shaped fibroblasts was slightly decreased in scars
after both series of injections (Figure 5a). The abundance of
TGF-b1 mRNA was significantly (Po0.05) inhibited in
scars after the series of 10 injections, but not the series of
3 injections (Figure 5b).
DISCUSSION
Hypertrophic scars and keloids are chronic diseases that may
enlarge for a few months or years. Keloids may remain for an
entire lifetime. These diseases are developed after external
injuries, burns, or surgical operations. Keloid diathesis is a
disease developed from minor wounds including common
acne, insect bites and stings, and vaccination sites. Complete
treatment for these diseases is clinically difficult, as there
have been no specific medicines developed.
Although the pathogenesis of these diseases remains
elusive, TGF-b1 has an important role in scar formation.
In the case of skin fibrosis, which was studied with
subcutaneous injections of TGF-b1 and CTGF into a murine
model with fibrotic skin, it was reported that type 1 collagen
and fibronectin are induced by both TGF-b1 and CTGF
(Mori et al., 1999). TGF-b has a pivotal role in inducing skin
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Figure 1. Changes in macroscopic and histopathological findings, and expression of growth factors and extracellular matrices in the incised skin.
(a) Changes in macroscopic and histopathological findings of hypertrophied scar formation in rats at 14, 28, and 42 days after skin incisions. The hypertrophic
scars were created dorsally by incisions into the skin with a scalpel. Four full-thickness, linear incisions, 1 cm in length, down to and including the
panniculus carnosus were made on the dorsal skin of rats. Skin samples were obtained from the scar lesions and 6-mm thick sections were stained with
hematoxylin–eosin. Eight incisions were made per experiment (biopsy site¼ 8). Representative data are shown in the figures because the changes were very
similar in each experiment. Bar¼5mm in macroscopic findings and 500 mm in histopathological findings. (b) Changes in mRNA expression of growth factors
(transforming growth factor-b1 (TGF-b1) and connective tissue growth factor (CTGF)) and extracellular matrices (collagen type1 and fibronectin) in
incisional wounds of skin. Total RNAs from the samples were extracted and reverse transcription PCR was performed. The values are expressed as the
mean±SE (n¼ 6). *Po0.05 versus day 0. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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fibrosis and CTGF is also required to maintain the fibrosis
response (Shinozaki et al., 1997). In the present study using
skin incisions in rats, expression of TGF-b1 mRNA increased
over time; its peak level was observed at day 3 and then
gradually reduced. It is possible that the increased transcrip-
tional activity of TGF-b1 was stimulated by cytokines from
inflammatory cells after the incision. In the immunohisto-
chemical findings, TGF-b1 staining was still detected in skin
scars 42 days after the incision. Interestingly, the time course
of changes in expression of CTGF and extracellular matrix
(collagen type1 and fibronectin) mRNAs was quite different
from that of TGF-b1. Changes in expression of CTGF mRNA
showed a minor peak 3 days after the incision, then gradually
increased after the temporary decrease. The CTGF gene
promoter has both an activator protein (AP)-1 site and a
response element binding to Smad as a second signal to the
TGF-b1 receptor (Grotendorst et al., 1996). Thus, it is
considered that the early increased expression of CTGF was
influenced by TGF-b1, but the second peak may be a direct
induction of CTGF by continuous stimulation through the
activation of AP-1.
PI polyamides have been the subject of intense study,
along with many other classes of minor groove binders.
Sequence-specific DNA recognition depends on side-by-side
aromatic amino-acid pairings in the minor groove. The
antiparallel pairing of imidazole opposite pyrrole recognizes
a GC base pair from CGAT and TA, whereas a pyrrole/
imidazole combination distinguishes CG from GC, TA, and
AT. A pyrrole/pyrrole pair is degenerate and recognizes either
an AT or TA base pair. These pairing rules have proven useful
for programmed recognition of a broad repertoire of DNA
sequences (Trauger et al., 1996; White et al., 1997),
especially for the binding sequence in transcription factors.
The initiation of transcription requires the binding of
transcription factors to the cognate DNA response elements
in the gene promoter. It has been reported that PI polyamides
targeting transcription factors were able to effectively
interfere with protein–DNA interfaces, blocking the binding
of transcription factors and modulating target gene expression
(Dervan et al., 2005).
In the present study, we established a rat model of
hypertrophic scarring in skin and performed several experi-
ments to evaluate the inhibitory effects of Polyamide on the
scars. Polyamide was designed and synthesized so as to show
specificity over the AP-1-binding site and to inhibit TGF-b1
promoter activity. FITC-labeled Polyamide was introduced
into almost all the nuclei of cells in the controls and
hypertrophic scars in rats, and then bound tightly to the
nuclei over a period of 96 hours. Thus, Polyamide was
effectively delivered and bound to the nuclei of the cells in
the skin after local injection and without any vectors or
delivery reagents.
We clearly demonstrate that injections of Polyamide at the
same time as skin incision almost completely prevented
hypertrophic scar formation in skin. We also showed that
treatment with Polyamide inhibited increases in collagen
fibers and the expression of TGF-b1 at the mRNA and protein
levels. Expression of CTGF and extracellular matrix (collagen
type1 and fibronectin) mRNAs was also markedly inhibited
with Polyamide. From these results, the ideal timing to
administer TGF-b1 PI polyamide may be before the rapid
increase in TGF-b1 mRNA and the peak of its expression.
This administration should be at the time of incision, or
within 1 or 2 days after the incision. As part of standard
clinical applications, it is considered that treatment with
Polyamide should occur at the time of wound closure in
Polyamide
DAPI
1 Hour 6 Hours 24 Hours 96 Hours
Figure 2. Distribution of FITC-labeled pyrrole–imidazole (PI) polyamide targeted to the rat transforming growth factor-b1 (TGF-b1) promoter in rat skin.
Ten mg of FITC-labeled PI polyamide were injected subcutaneously into rat skin just after incision. The skin excised at each indicated time point was
immediately embedded in OCT compound and frozen in liquid nitrogen. Nuclei were stained with 40-6-diamidino-2-phenylindole (DAPI). Bar¼ 500mm
(original magnification  400).
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surgery, or at the earliest possible opportunity in the case of
burns and traumatic wounds so as to prevent the develop-
ment of keloids and hypertrophic scars.
To examine whether Polyamide inhibits established
hypertrophic scars, we injected Polyamide into hypertrophic
scars at 42 days after incision in rats. As a result, there was a
reduction in grossly visible scar elevations, but this effect was
not complete, having a strong suppression of TGF-b1 but not
resulting in a strong inhibitory effect on fibrosis, according to
histological examination. TGF-b1 staining was still observed
42 days after incision in the controls in the present
experiments. For patients with keloid diathesis, progression
of fibrosis is continued even after the completion of scar
formation. It is considered therefore that repeated adminis-
tration of Polyamide for a longer period may be effective for
established scars.
Recently much attention has been paid toward low-
molecular-weight inhibitors of TGF-b1 receptors and there
are various studies related to them. For example, there have
been reports showing that an inhibitor of TGF-b type 1
receptor kinase activity, SB-431542, inhibits TGF-b-induced
contraction of collagen gels by normal and keloid fibroblasts
(Grotendorst et al., 1996; Hasegawa et al., 2005), suggesting
that this compound may have therapeutic potential for the
excessive skin contraction that is observed in keloids. In
addition, a (to our knowledge) previously unreported
truncated TGF-b receptor II (tTGFbRII) had excellent inhibi-
tory effects on the growth of keloid fibroblasts, their synthesis
of collagen type1 and expression of TGF-b (Chu et al., 2008).
They showed that treatment with tTGFbRII inhibited the TGF-
b1 expression at both the mRNA and protein levels.
Thus, molecules responsible for various intractable
diseases have been identified, which opened the way to
develop nucleic acid medicines targeting diseases without
established treatments. Owing to their DNA or RNA
structure, nucleic acid drugs are promptly decomposed by
enzymes when administered in vivo. PI polyamides, which
are resistant to these nucleolytic enzymes, can bind base
sequence-specifically to double-stranded DNA like other
nucleic acid drugs. Moreover, they can be delivered to cells
or tissues without using vectors or delivery reagents (Lai et al.,
2005). Fukusawa et al. (2009) established a high-performance
liquid chromatography measurement method for PI poly-
amide and systematically administered PI polyamide to rats
by the parenteral route to evaluate its pharmacokinetic effect
and demonstrated that PI polyamides show the same
pharmacokinetic effects as regular drugs in serum. Hence
PI polyamide is now expected to be a novel medicine that
acts as a gene silencer to transcriptionally regulate target
diseases. The transcriptional regulation of the TGF-b1
promoter at the AP-1-binding site by Polyamide is advanta-
geous in terms of side effects, as Polyamide inhibits the
expression of TGF-b1 induced in disease states where
transcription is activated, but does not affect expression in
normal states. We recently demonstrated that a long-term
administration of Polyamide effectively ameliorates progres-
sive renal diseases in hypertensive rats without any side
effects (Matsuda et al., 2011).
There are several hurdles for the future drug development
of PI polyamide targeted to TGF-b1. One of those hurdles is
specificity to the TGF-b1 gene promoter, because Polyamide
may also inhibit transcriptional control of other genes that
have homologous promoters. To get the specificity of
Polyamide to TGF-b1 promoter, Polyamide was designed
not to cover AP-1 consensus sequences, but spans the
boundary of AP-1-binding site with the intention of obtaining
specificity to the promoter. This Polyamide showed strong,
fast, and specific binding to the target DNA in gel mobility
shift and Biacore assays (Matsuda et al. 2006). We recently
evaluated the specificity by a microarray analysis and
demonstrated that growth factors and extracellular matrices
are specifically inhibited with Polyamide, whereas there was
little effect on the expression of other genes (Matsuda et al.,
2011). In addition, administration methods of PI polyamides
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Figure 3. Effects of pyrrole–imidazole (PI) polyamide targeted to TGF-b1
promoter on the expression of transforming growth factor (TGF)-b1 mRNA
and protein in hypertrophic scars on rat skin. The hypertrophic scar was
created on the back by skin incisions with a scalpel. (a) Doses of 1 to 100 mg
of TGF-b1-targeted PI polyamide (Polyamide) were injected subcutaneously
into wounds just after skin incisions. Total RNAs from scar lesion samples
were extracted and reverse transcription PCR was performed. (b) One
hundred mg of Polyamide or mismatch polyamide (Mismatch) were injected
into wounds just after skin incisions and the resulting expression of TGF-b1
protein was determined by western blot analysis. The values are expressed as
the mean±SE (n¼ 6). *Po0.05 versus injection of saline (control). GAPDH,
glyceraldehyde-3-phosphate dehydrogenase.
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also should be considered when applied in clinical settings.
The molecular weight of the PI polyamide is about 17,000,
which is supposedly difficult to be transdermally absorbed
via the horny cell layer. In the present study, PI polyamide
was locally injected, however, the development of external
applications with absorption promoters or a drug delivery
system such as iontophoresis should be actively investigated.
If these problems are resolved, the PI polyamide will be
feasible as a treatment for transcriptionally inhibiting the
TGF-b1 that causes hypertrophic and keloid scarring.
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Figure 4. Effects of pyrrole-imidazole polyamide targeted to the transforming growth factor (TGF)-b1 promoter (Polyamide) on the fibrosis and the
expression of growth factors and extracellular matrix mRNAs in skin scars. (a) Effects of Polyamide on development, histopathology, and stainings of TGF-b1
and vimentin in hypertrophic scars in rat skin. Hypertrophic scars were created on the back by skin incisions with a scalpel. Skin samples were obtained from
scar lesions and 6-mm thick sections were stained with hematoxylin–eosin. Eight incisions were made per experiment (biopsy site¼ 8). Representative data
are shown in the figures because the changes were very similar in each experiment. (b) Effects of Polyamide on expression of growth factor (TGF-b1 and
connective tissue growth factor (CTGF)) and extracellular matrix (collagen type1 and fibronectin) mRNAs in incisional wounds. The values are expressed
as the mean±SE (n¼6). *Po0.05 versus mismatch PI polyamide. Bar¼ 5mm in macroscopic findings, 500 mm in histopathological findings, and 50 mm in
histological findings. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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MATERIALS AND METHODS
Ethics
This study conformed to the standards of the Guide for the Care and
Use of Laboratory Animals published by the US National Institutes of
Health (NIH Publication No. 85-23, revised 1996) and approved by
Nihon University Institutional Animal Care and Use committee.
Synthesis of polyamide
In brief, rat Polyamide was designed to span the boundary of the
AP-1-binding site (2,303 to 2,297) of the TGF-b1 promoter
(Figure 6a). Numbering refers to the start of the open-reading frame
as 1. A mismatch polyamide (Mismatch) was designed as one
imidazole–pyrrole substitution and different position of b-linker to
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Figure 5. Effect of pyrrole–imidazole (PI) polyamide targeted to the transforming growth factor-b1 (TGF-b1) promoter on established hypertrophic scars
on rat skin. Established hypertrophic scars were created on the dorsal skin by incision with a scalpel and left to develop for 42 days. TGF-b1-targeted
PI polyamide (Polyamide) was subsequently injected at 3-day intervals during a series of either 3 or 10 groups of injections around the scars and the skin
samples were obtained from the scar lesions. (a) Six-mm thick sections were stained with hematoxylin–eosin and used to evaluate TGF-b1 and vimentin
immunohistochemically. (b) Effects of Polyamide on expression of TGF-b1 mRNA in incisional wounds of established hypertrophic scars. The values are
expressed as the mean±SE (n¼6). *Po0.05 versus injection of saline (control). Bar¼5mm in macroscopic findings, 500 mm in histopathological findings,
and 50 mm in histological findings. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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target different DNA sequence and was not able to bind to the AP-1
site of TGF-b1. All of the PI polyamides were synthesized with a
machine-assisted automatic synthesis system, the PSSM-8 Peptide
Synthesizer (Shimadzu, Kyoto, Japan).
Animals and creation of skin hypertrophic scar in rats
Hypertrophic scars were created on the dorsal skin surface
by incisions with a scalpel. Adult male Sprague–Dawley rats
(Clea Japan, Tokyo, Japan) weighing 225–250 g were anaesthetized
by pentobarbital natrium. Four full-thickness, linear incisions, 1 cm
in length, down to and including the panniculus carnosus were
made on the dorsal skin of rats. The incisions were placed
equidistant from the midline and adjacent to the four limbs and in
the majority of experiments four incisions were made per rat.
Distribution of FITC-labeled PI polyamide in rat skin
To evaluate the distribution of Polyamide in rat skin, we injected
subcutaneously 10 mg of FITC-labeled Polyamide in 500ml of a
0.02%. DMSO solution. The skin excised at each indicated time
point after injection was immediately embedded in OCT compound
(Miles, Elkhart, IN) and frozen in liquid nitrogen. The distribution of
the FITC-labeled Polyamide was confirmed using an inverted
fluorescence microscope (Eclipse TE-2000-U, Nikon, Tokyo, Japan).
Dissolution of polyamide and its application to rat skin
Polyamide and Mismatch (1–100 mg) were dissolved in 500ml of a
0.1% acetic acid solution. The polyamides were injected subcuta-
neously with a 25G needle (Terumo, Tokyo, Japan) just after skin
incisions at four symmetrical points surrounding the incisions.
We also injected polyamides after the full development of scarring.
Determination of mRNA expression
After the incision and the injection of PI polyamides, skin tissue
samples were collected preoperatively from the incision wound.
Total RNAs from samples were extracted with ISOGEN (Nippon
Gene, Tokyo, Japan). Reverse transcription PCR was performed
with the 2720 Thermal cycler (Applied Biosystems LLC, Foster City,
CA) using TaKaRa Ex Taq (Takara Bio, Tokyo, Japan). Primer
sequences are listed in Supplementary Table S1 online. PCR
products were assayed on the Agilent 2100 Bioanalyzer (Agilent
Technologies, Berlin, Germany).
Determination of the expression of TGF-b1 protein
Expression of TGF-b1 protein in skin incision wounds was
determined by western blot analysis by using an enhanced
chemiluminescence detection system (Perkin Elmer, Waltham,
MA). Skin tissues were treated with a hypotonic 50mM Tris-HCl
buffer (pH 7.4) containing protease inhibitors. Equal amounts of
tissue protein were loaded into each well and separated by 10%
SDS-PAGE. Briefly, each sample prepared from skin was separated
by SDS-PAGE and was transferred to a nitrocellulose membrane and
analyzed with anti-TGF-b1 antibody: sc-146 (Santa Cruz Biotech-
nology, Santa Cruz, CA), anti-a-tubulin antibody: T-9026, and
horseradish peroxidase-labeled secondary antibody (Sigma-Aldrich
Life Science, Tokyo, Japan). They were visualized with an LAS-3000
(Fujifilm, Tokyo, Japan) luminescent image analyzer and then the
expression levels of TGF-b1 were standardized with those of
a-tubulin. Four samples were used per experiment.
Histopathological and immunohistochemical examinations
Skin samples obtained from scar lesions and control sites were fixed
in 10% neutral-buffered formalin and embedded in paraffin. Sections
of 6mm thick were stained with hematoxylin–eosin, and deparaffi-
nized, dehydrated in a routine manner, and incubated at 4 1C
overnight with antihuman vimentin mouse mAb (1:1,000; Novocas-
tra, Tokyo, Japan) and TGF-b1 antihuman TGF-b1 rabbit polyclonal
antibody (1:1,000; Yanaihara, Shizuoka, Japan). Eight incisions were
used per experiment (biopsy site¼ 8). Representative data have been
shown in the figures, because there were very similar changes in
each experiment.
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Figure 6. Target sequence and structure of the synthetic pyrrole–imidazole
(PI) polyamide that targets the rat transforming growth factor-b1 (TGF-b1)
promoter. (a) The polyamide was designed to bind to the rat TGF-b1
promoter adjacent to the activator protein-1-binding site (TGAGTCA, 2,303
to 2,297). (b) Structure of the rat TGF-b1 specific polyamide (Polyamide)
and mismatch polyamide (Mismatch). Mismatch was designed not to bind
to the transcription-binding sites of the promoter. PI polyamides were
synthesized by solid phase methods and were purified by high-performance
liquid chromatography (0.1% AcOH/CH3CN 0–50% linear gradient,
0–40minutes, 254 nm through a Chemcobond 5-ODS-H column,
Chemco Scientific, Osaka, Japan). Im, imidazole; Py, pyrrole.
1994 Journal of Investigative Dermatology (2011), Volume 131
H Washio et al.
TGF-b1 Silencer on Hypertrophic Scars
Statistical analyses
The values are reported as the mean±SE. Student’s t-test was used
for unpaired data. Two-way analysis of variance with the Bonferroni/
Dunn procedure as post-test was also used. Po0.05 was considered
to be statistically significant.
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